secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001711279-25-000055
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhaled KB707 monotherapy achieves 27% ORR in advanced NSCLC; updated to 36%
----------------------------------------------------------------------------

- 27% ORR (3/11 PR) in heavily pre-treated NSCLC; extended follow-up yields 36% (4/11 PR).
- Median DOR and PFS not reached; responses durable.
- Safety well-tolerated: most TRAEs Grade 1/2, no Grade 4/5; MTD not reached.
- Combination cohort with pembrolizumab enrolling for NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000055/0001711279-25-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000055/krys-20250602.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer